Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Statements of Operations and Comprehensive Loss

v3.25.2
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Consolidated Statements of Operations and Comprehensive Loss    
Revenue $ 400,000 $ 225,000
Operating expenses:    
Research and development 8,312,000 5,185,000
General and administrative 10,690,000 11,674,000
Total operating expenses 19,002,000 16,859,000
Operating loss (18,602,000) (16,634,000)
Other income (expense):    
Interest expense (212,000) (172,000)
Interest income 437,000 363,000
Gain on sale of intellectual property   1,000,000
Total other income 225,000 1,191,000
Net loss from continuing operations (18,377,000) (15,443,000)
Loss from discontinued operations   (9,464,000)
Net loss $ (18,377,000) $ (24,907,000)
Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations $ (1.75) $ (4.03)
Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations (1.75) (4.03)
Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations   (2.47)
Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations   (2.47)
Loss per common share attributable to iBio, Inc. stockholders - basic - total (1.75) (6.5)
Loss per common share attributable to iBio, Inc. stockholders - diluted - total $ (1.75) $ (6.5)
Weighted-average common shares outstanding - basic 10,499 3,831
Weighted-average common shares outstanding - diluted 10,499 3,831